首页 | 本学科首页   官方微博 | 高级检索  
     

胰高血糖素样肽-1改善非酒精性脂肪性肝病作用机制研究进展*
引用本文:信丰智 综述,曹海霞,范建高 审校. 胰高血糖素样肽-1改善非酒精性脂肪性肝病作用机制研究进展*[J]. 实用肝脏病杂志, 2018, 21(2): 313-316. DOI: 10.3969/j.issn.1672-5069.2018.02.047
作者姓名:信丰智 综述  曹海霞  范建高 审校
作者单位:200092 上海市 上海交通大学医学院附属新华医院消化内科
基金项目:*国家自然科学基金资助项目(编号:81270491)
摘    要:近期研究表明,胰高血糖素样肽-1受体激动剂可从改善肝细胞脂质代谢、抑制炎症反应、调节细胞自噬等多个环节减轻非酒精性脂肪性肝病(NAFLD)患者肝脏脂质沉积,改善组织学损伤,有望成为治疗NAFLD药物的新选择。

关 键 词:非酒精性脂肪性肝病  胰高血糖素样肽-1  作用机制  
收稿时间:2017-01-10

Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease
Xin Fengzhi,Cao Haixia,Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 21(2): 313-316. DOI: 10.3969/j.issn.1672-5069.2018.02.047
Authors:Xin Fengzhi  Cao Haixia  Fan Jiangao
Affiliation:Department of Gastroenterology,Xinhua Hospital,JiaoTong University School of Medicine,Shanghai 200092,China
Abstract:Glucagon-like peptide-1 receptor agonists could meliorate hepatic lipid deposition and histological damage by regulating lipid metabolism,inflammation and autophagy in pathogenesis of non-alcoholic fatty liver disease (NAFLD),which may serve as a new option for treatment of patients with NAFLD.
Keywords:Non-alcoholic fatty liver disease  Glucagon-like peptide 1  Pathogenesis  
点击此处可从《实用肝脏病杂志》浏览原始摘要信息
点击此处可从《实用肝脏病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号